We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Thallion Announces First Patient Enrolled In High Dose Cohort of Phase II SHIGATEC Trial
Product News

Thallion Announces First Patient Enrolled In High Dose Cohort of Phase II SHIGATEC Trial

Thallion Announces First Patient Enrolled In High Dose Cohort of Phase II SHIGATEC Trial
Product News

Thallion Announces First Patient Enrolled In High Dose Cohort of Phase II SHIGATEC Trial


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Thallion Announces First Patient Enrolled In High Dose Cohort of Phase II SHIGATEC Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Thallion Pharmaceuticals Inc. and LFB Biotechnologies have announced the enrollment of the first patient in the high dose cohort of the Company's Phase II SHIGATEC trial.

The high dose cohort (3 mg/kg/dose) is expected to enroll 21 patients which will complete the Phase II trial evaluating Shigamabs® as a treatment for Shiga toxin-producing E. coli (STEC) infection. The Company anticipates top line results to be available prior to the end of the year.

"Following the positive recommendation from the IDMC after the low dose cohort and the resumption of patient enrollment in our SHIGATEC trial, we continue to push forward with the clinical development of our novel Shigamabs® treatment. Shigamabs® represents the most advanced clinical treatment in development for the prevention of a condition in which the current standard of care is simply to hydrate, wait and then monitor disease progression," said Dr. Allan Mandelzys, Chief Executive Officer of Thallion Pharmaceuticals Inc.

"We believe a clear medical need exists for the treatment of STEC infections, and the recent German outbreak, where approximately 300 cases of haemolytic uraemic syndrome (HUS) and 10 deaths have been reported, is an unfortunate reminder of that," said Guillaume Bologna executive Vice-President for Development Programs of LFB Biotechnologies.

Advertisement